Floatz Rating
B60/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07223567CT.gov A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer | — | Withdrawn | — | — | — |
NCT06911684CT.gov Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. | — | Recruiting | — | — | — |
NCT06575725CT.gov Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | — | Withdrawn | — | — | — |
NCT05900648CT.gov Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | — | Withdrawn | — | — | — |
NCT04503694CT.gov Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04362839CT.gov Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02287727CT.gov Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Regorafenib (this asset) | M.D. Anderson Cancer Center | P2 | B · 60 |
| Irinotecan | Sun Yat-sen University | P4 | BBB |
| Fluorouracilum | Seoul National University Hospital | P3 | BBB |
| Oxaliplatin | Sun Yat-sen University | P3 | BBB |
| Capecitabine | Tao Zhang | P3 | BB |
| Indocyanine Green | National Cancer Center, China | P3 | BB |
| Cetuximab | Fudan University | P3 | BB |
| Tipiracil | Academic and Community Cancer Research United | P2 | BB |
| Floxuridine | City of Hope Medical Center | P2 | BB |
+42 more in the Rectal Cancer cohort
Other indications for Regorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 73 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
| Colorectal Adenocarcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Regorafenib in Rectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/regorafenib-rectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →